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ABSTRACT 
Background 
Fecal microbiota transfer (FMT) is an effective treatment for recurrent C. difficile infection 
(CDI), but data on procedure-related complications and long-term outcome are scarce. 
Methods 
All patients treated with FMT for recurrent CDI at the Academic Medical Center between 
July 2010 and January 2016 were included. FMT was performed according to the FECAL 
trial protocol: administration of fresh donor feces (related or unrelated donor) through a 
duodenal tube after pre-treatment with vancomycin and bowel lavage. We collected 
information on FMT-related complications, recurrent CDI, and short- and long-term 
adverse events by telephone interviews using a structured questionnaire at three months 
after FMT, and at the time of data collection of this study. 
Results 
In total, 39 patients were treated with FMT. The primary cure rate (no recurrence eight 
weeks after one infusion with donor feces) was 82% (32 of 39 patients). Of the seven 
patients with recurrent CDI after FMT, four were cured by antibiotic therapy alone 
(fidaxomicin in three patients, metronidazole in one patient) and three by repeat FMT. 
Peri-procedural complications occurred in five patients, comprising fecal regurgitation or 
vomiting. One patient died one week post-FMT due to pneumonia; a causal relation with 
FMT could not be excluded. The follow-up period ranged between 3 and 68 months. No 
long-term side effects were reported. 
Conclusions 
Our data underline the efficacy of FMT as treatment for recurrent CDI. Importantly, it is 
possible to cure post-FMT recurrences with antibiotic therapy alone. Peri-procedural 
complications do occur and should be closely monitored to help identify high-risk patients. 
To minimize the risk of complications, all FMT candidates should be evaluated to assess 
the most ideal delivery method. 
INTRODUCTION 
Clostridium difficile is the most common cause of nosocomial diarrhea and healthcare-
associated infection.1,2 Symptoms of C. difficile infection (CDI) range from self-limiting 
disease to fulminant colitis. The estimated recurrence rate after treatment of an initial 
healthcare-associated CDI is 20-25%, with increased risk of recurrence (up to 80%) 
after each subsequent CDI episode.3,4 Persistent disruption of the intestinal 
microbiota, mostly caused by the use of antibiotics, is the most important cause of 
recurrent CDI.5 Even antibiotics used to treat CDI, such as oral vancomycin, influence 
the balance of the microbiota.6  
Use of fecal microbiota transfer (FMT) has gained momentum across the globe, since 
it was established as a highly effective method to recurrent CDI, with cure rates 
around 85%.7,8 FMT leads to the restoration of the gut microbiota, resulting in 
colonization resistance preventing germination of C. difficile spores. However, 
worldwide implementation of FMT is currently limited by a lack of uniform guidelines, 
concerns about safety, and remaining uncertainty of long-term side effects. A recent 
review of the literature about adverse events in FMT reported three deaths 
potentially attributable to FMT for CDI9, including septic shock with decompensated 
toxic megacolon10, aspiration during sedation for colonoscopy11, and fatal aspiration 
pneumonia.12 One case of micro perforation after biopsy and one case of cecal 
perforation necessitating colectomy have been described.13,14 Norovirus transmission 
possibly associated with FMT has been reported in two cases.15 Mild short-term side 
effects include diarrhea, flatulence, transient abdominal discomfort and 
bloating.7,9,13,16-18  
More follow-up data are needed to capture the efficacy and safety profile of FMT. 
Here we report the results of follow-up of patients who were treated with FMT at the 
Academic Medical Center (AMC), Amsterdam.  
METHODS 
Participants 
We included all patients treated with FMT for recurrent CDI between July 2010 and 
January 2016, at the AMC in Amsterdam, The Netherlands (after termination of the 
FECAL trial).7 Patients (18 years) were referred from across The Netherlands, and 
were evaluated by an infectious disease specialist (authors AG and EN) to determine 
eligibility before they received FMT. Pregnancy and antibiotic usage other than for C. 
difficile at the day of the expected infusion were absolute exclusion criteria for FMT 
treatment. All patients had documented recurrent CDI after at least one course of 
adequate CDI antibiotic therapy. Recurrent CDI was defined as the reappearance of 
diarrhea (three unformed stools per 24 hours) in combination with a positive C. 
difficile toxin ELISA (after June 2015 toxin PCR). The potential risks, benefits, logistics, 
and procedural details were discussed during an outpatient clinic visit. If the patient 
had any acute medical conditions other than CDI on the day of donor feces infusion, 
FMT was rescheduled. Patients gave oral consent for anonymous use of their data for 
scientific purposes. 
Fecal microbiota transfer 
The collection and infusion of donor feces was performed according to the protocol 
used in the FECAL trial.7 In summary, fresh donor feces was obtained from an adult 
family member (e.g. spouse, brother or sister, son or daughter) or an anonymous 
young healthy donor, after screening for infectious diseases (the anonymous donor 
was screened every three months).7 Donor feces was collected on the day of infusion 
and diluted with 500 mL of sterile saline (0.9%). This solution was poured through an 
unfolded gauze in a sterile bottle. On the day of FMT a nasoduodenal tube was placed 
under direct imaging, using Cortrak electromagnetic imaging system. Within six hours 
after collection of feces by the donor, the donor feces solution was slowly 
administered to the patient through a nasoduodenal tube (two minutes per 50 mL 
syringe, with a break of at least half an hour after 250 mL). Prior to FMT, until one day 
before the procedure, patients received vancomycin (250 mg QID) for a minimum of 
four days, followed by bowel lavage one day prior to FMT. 
Pre- and post-FMT data 
Pre- and post-FMT data were collected from all patients. Pre-FMT data included 
patient demographics, health status, and number and type of previous failed 
treatment courses. Short-term (<6 months) and long-term (6 months) post-FMT data 
were obtained by telephone interviews by their treating physician. Shortly after the 
procedure, and at three months after the procedure, patients were questioned about 
the occurrence of diarrhea, recurrent CDI, the use of antibiotics, and short-term 
adverse events (e.g. diarrhea, abdominal cramps, nausea, vomiting) in the context of 
standard patient care. At the time of data collection of this study patients were 
questioned about the occurrence of late recurrences, the use of antibiotics, and long-
term adverse events (e.g. infectious complications, development of auto-immune 
diseases, metabolic disorders, obesity, hospital admissions) using a structured 
questionnaire (see Appendix A). Also, medical charts were reviewed for additional 
data about recurrences, hospital visits, and hospital admissions. 
Primary cure was defined on clinical grounds as absence of diarrhea after initial FMT 
with no recurrence in the subsequent eight weeks. Because patients were referred 
from all parts of the country, it was not feasible to obtain post-FMT stool samples to 
confirm resolution of CDI with a repeat toxin test. Secondary cure was defined as the 
resolution of symptoms subsequent to repeat treatment with antibiotics and/or 
second FMT, in the case of recurrent CDI within eight weeks following initial FMT. The 
treating physician was interviewed, and medical charts were reviewed for data on the 
procedure, and procedure-related complications. A serious adverse event (SAE) was 
defined as any death, unplanned hospitalization or extension of the admission, or 
important medical event within 12 weeks after FMT. Following the World Health 
Organization-Uppsala Monitoring Centre (WHO-UMC) causality assessment system 




Between July 2010 and January 2016, 43 patients were treated with FMT for recurrent 
CDI. Four patients (9%) were lost to follow-up; therefore 39 patients were included in 
this study. Patient characteristics and pre-FMT data are shown in Table 1. The median 
age of the treated patients was 73 years (range 17-97 years). Data on pre-FMT 
antibiotic treatment for CDI were missing in 12 of 39 patients (31%). Antibiotic 
treatment for CDI had failed in all patients. Regimens included metronidazole (21/27 
patients), oral vancomycin in standard (25/27) or pulse-tapered regimens (15/27), 
and/or fidaxomicin (15/27). The time between the first episode of CDI and FMT 
ranged from 3 to 25 months. 
 
Table 1. Patient characteristics and pre-FMT data (N = 39) 
Patient characteristics   
Age in years, median (range)  73 (17-97) 
Male, N (%) 16 (41) 
Charlson comorbidity index19, mean (± SD) 3.0 (± 2.9) 
Recurrences of CDI, median (range)a 4 (3-10) 
Antibiotic courses, mean (range)b 
Metronidazole, N (%) 
Vancomycin, N (%) 
Tapered vancomycin, N (%) 











Time between first episode of CDI and FMT in months, median (range)* 6 (3-25) 
aData are missing for 4 patients (10%); bData are missing for 12 patients (31%). Abbreviations: SD: 
standard deviation; CDI: Clostridium difficile infection; FMT: fecal microbiota transplantation.  
  
Follow-up data 
Follow-up was assessed in 39 patients (Table 2). For 37 patients the follow-up was 6 
months. Of this cohort, 32 patients were successfully cured with FMT, yielding a 
primary cure rate of 82%. Seven patients experienced an early (eight weeks post-FMT) 
CDI recurrence. In two of these, CDI recurrence was associated with use of antibiotics 
within eight weeks after FMT. In the other five patients, no antibiotics had been 
prescribed post-FMT. 
 
Table 2. Post-FMT data (N = 39) 
 N % 
Primary cure of FMTa 32 82 
Recurrent CDI after FMTa 
Early recurrence (≤ 8 weeks) 










Serious adverse event within 12 weeks after FMT 
Procedure related (all probably related) 
Medical event (vomiting/regurgitation donor feces) 
Death 
Material related 
Unplanned hospitalization (possibly related) 















Short follow-up (< 6 months)  





Follow-up period in months – median (range) 21 3-68 
Long term side effects 0 0 
aData are missing for 1 patient (4%) 
 
Recurrent CDI post-FMT was successfully treated with antibiotics alone in four of 
seven patients, without subsequent need of a repeat FMT. Of these, one patient was 
treated with metronidazole and three with fidaxomicin. The other three patients were 
successfully treated with a repeat FMT, of which one had first been treated with 
fidaxomicin but had relapsed a few weeks post treatment. 
For one patient the indication of FMT had been dubious; previous CDI episodes were 
diagnosed based on ongoing diarrhea in combination with an inconclusive stool toxin 
test result for C. difficile. In addition, the patient had not responded at all to earlier 
treatments with either metronidazole, vancomycin, or fidaxomicin, during which 
diarrhea had persisted. This patient did also not respond to FMT, after which his 
symptoms remained unchanged. An alternative diagnosis was considered, for which 
he was referred to a gastroenterologist. 
Fifteen patients (38%) received donor feces from a family member, 24 (62%) from an 
anonymous donor. There was no statistically significant difference in the development 
of recurrent CDI between these groups (3/15 in the family donor group versus 4/24 in 
the anonymous donor group, p = 0.79). 
Seven patients died after the 12-week post-FMT period (range 4-28 months). None of 
these were related to CDI or FMT, all were associated with pre-existing chronic 
progressive illnesses (progressive cholangiocarcinoma, metastatic stomach cancer, 
Alzheimer's disease, pulmonary embolus, acute myocardial infarct, heart failure, renal 
insufficiency). 
Serious adverse events 
SAEs were observed in nine patients within 12 weeks post-FMT of which five (12%) 
were (probably) related to the FMT procedure: one patient died, and four patients 
experienced a medical event (Figure 1). One patient (3%) was hospitalized after FMT 
which was possibly related to the FMT material. 
One patient died 15 days after FMT due to pneumonia; a causal relation with FMT 
could not be excluded. This patient was fed through a PEG tube because of a 
swallowing disorder following oropharyngeal radiation after surgical removal of a 
maxillary carcinoma two years earlier. The donor feces was administered through 
nasoduodenal tube, which was placed (without sedation) besides the PEG tube. In the 
three-hour observation period after FMT, the patient had experienced some 
regurgitation, which at that moment did not appear to be severe. However, within 
one week after FMT, the patient developed pneumonia and died despite antibiotic 
treatment. Although no causative organism was identified, possible aspiration of 
donor feces could have been the cause of this pneumonia. 
 
 
Figure 1. Serious adverse events within 12 weeks after FMT (possibly or probably related). 
 
Procedural complications were observed in four other patients. The first patient, 
following uncomplicated FMT delivery, consumed a meal within one hour after FMT, 
after which the patient developed nausea and subsequent vomiting. The second 
patient had a medical history of continuous ambulatory peritoneal dialysis. During 
administration of the first half of donor feces suspension the patient experienced 
some abdominal cramps. Therefore, administration of the second half of donor feces 
suspension (250 mL) was postponed. After an observation period of one hour, during 
which the abdominal cramps had resolved, the second half of donor feces suspension 
was administered, and FMT was completed. However, shortly after the FMT 
procedure, the patient developed acute diarrhea and nausea, with subsequent 
vomiting. The third patient had a history of a congenital syndrome, which included 
mental retardation and a swallowing disorder. The patient was fed by PEG tube. This 






Hospitalization < 12 weeks after FMT
Regurgitation
Vomiting
No serious adverse event
discontinuation of the procedure, removal of the nasoduodenal tube and a symptom 
free post-FMT observation period of three hours, the patient vomited on the way 
home after discharge from the hospital. In the fourth patient, FMT was immediately 
halted and the nasoduodenal tube removed, when nausea and mild regurgitation 
occurred, after which symptoms resolved. None of these four patients developed 
further complications. One of these patients developed a post-FMT recurrence, which 
was successfully cured by a 10-day course of fidaxomicin. 
Three patients were hospitalized within 12 weeks after FMT, with problems unrelated 
to FMT or recurrent CDI. One patient was admitted one month post-FMT with 
symptoms of vomiting and diarrhea, which could have been related to the FMT 
material. The stool sample of this patient was positive for both Yersinia enterocolitica 
and C. difficile. At the time of screening, the donor feces had been screened negative 
for these pathogens. Although the donor may have acquired Y. enterocolitica after the 
screening, the incubation time makes it very unlikely that the Y. enterocolitica 
infection was caused by FMT. The diarrhea resolved after treatment of the Y. 
enterocolitica infection only, without treatment for CDI. However, two months later 
the patient developed diarrhea again, with a positive stool toxin test for C. difficile (Y. 
enterocolitica negative). The patient was then successfully treated with a 10-day 
course of fidaxomicin and did not experience a relapse since (follow-up 36 months). 
 
DISCUSSION 
Further implementation of FMT is hampered by the lack of uniform guidelines, 
concerns about safety, and remaining uncertainty about long-term side effects. With 
a primary cure rate of 82% in 39 patients, this study supports the currently available 
evidence that FMT is a very effective treatment for recurrent CDI. Importantly, four of 
seven patients who experienced a post-FMT recurrence were successfully cured by 
antibiotic therapy alone, without the need of repeat FMT. This suggests that patients 
treated with FMT for recurrent CDI may have a partially restored microbiota reflected 
by increased efficacy of antibiotic treatment compared to the pre-FMT state. We now 
treat a first recurrence of CDI after FMT always with antibiotics, with a preference for 
fidaxomicin, because of the narrow antibiotic spectrum associated with the lowest 
risk of recurrence in this high-risk patient group.20 In two patients, recurrent CDI was 
associated with use of antibiotics within 12 weeks after FMT. This finding suggests 
that for the restoration of the gut microbiota by FMT, the early period is crucial. 
Therefore we recommend to avoid antibiotics during the first month after FMT unless 
strictly necessary. 
A classic feature of recurrent CDI is the resolution of symptoms during antibiotic 
treatment, but rapid recurrence of symptoms after cessation of antibiotic therapy. 
When patients do not respond to antibiotic treatment at all, as illustrated by one 
patient in this study, it should be questioned whether CDI is the actual cause of 
symptoms before proceeding to treatment with FMT. 
In general, FMT is considered to be safe. In our cohort, with a follow-up period of 
more than five years in some patients, no long-term side effects (e.g. infectious 
complications, auto-immune disease, obesity, diabetes) were reported. However, five 
of 39 patients (13%) experienced regurgitation or vomiting after FMT by 
nasoduodenal tube. One of these patients died due to pneumonia two weeks after 
FMT. The possibility of aspiration due to FMT could not be excluded. Regurgitation or 
vomiting after FMT has been described earlier in a case series11,21, and one case 
report12, and seems the main concern of FMT through a duodenal tube compared to 
FMT via colonoscopy or enema. In our cohort the amount of donor feces suspension 
(500 mL) could have contributed to this complication. We have adjusted our protocol 
to prevent this complication by reducing the load of the macrogol solution prior to the 
procedure, and by reducing the volume of the donor feces suspension to a maximum 
of 200 mL, if the patient develops abdominal discomfort or nausea. It is suggested 
that the required amount of donor feces is 50g.22 Therefore, it might be well possible 
to further decrease this volume. With the advent of lower volume solutions or oral 
capsules derived from stored frozen samples23,24 the problem of 
regurgitation/vomiting may become less prominent. 
Other preventive measures to avoid regurgitation or vomiting are: 
- Reduce stress/anxiety. 
- Avoid ingestion of food or fluids shortly (<1 hour) after FMT. 
- Use caution with pre-existing abdominal conditions (such as a calcified gut 
secondary to chronic peritoneal dialysis in one of our patients). 
- In case of patients who are fed across a PEG tube, consider consultation of a 
gastroenterologist, who can pass a jejunal extension through the PEG tube. 
- Assess aspiration risk in each patient, and if increased consider administration of 
FMT via colonoscopy. 
- Patients with a swallowing disorder should be excluded from FMT via a 
nasoduodenal tube. 
- During FMT, perform continuous monitoring of symptoms of abdominal 
discomfort or nausea, and discontinue FMT immediately when symptoms 
develop. 
- If nausea develops, consider administration of metoclopramide. 
- After FMT, patients should be observed in the hospital for at least three hours. 
Donor feces is usually administered through a nasogastric or duodenal tube, 
colonoscopy, or enema. All methods have advantages and disadvantages, and in every 
patient the ideal delivery route should be assessed. In general, we prefer FMT delivery 
through a duodenal tube, because it is generally well tolerated by patients and less 
invasive compared to colonoscopy.11,25 In particular, use of the Cortrak 
electromagnetic imaging system, enables safe, accurate and deep intra-duodenal 
positioning of the tube at patient's bedside without assistance of endoscopy (and 
sedation). In our cohort, patients received bowel lavage before FMT in attempt to 
remove the pre-existent flora, and C. difficile spores prior to FMT.7 This may, however, 
not be necessary, since there are reports on FMT via upper gastrointestinal delivery 
(upper FMT) without bowel lavage, with similar effectiveness.21,26,27 To date, we have 
performed upper-FMT without bowel lavage in three patients (for various reasons), all 
of whom responded well. Because bowel lavage is considered to be the most 
inconvenient part of FMT (Van Nood et al.; submitted for publication), a study 
comparing upper-FMT with and without bowel lavage would be welcome. If 
effectiveness would be equal, bowel lavage could be discarded, greatly increasing 
patient comfort. Furthermore it would support the use of the upper gastrointestinal 
route. Administration through colonoscopy has the advantage of visibility of relevant 
pathology, and the capacity to infuse larger volume suspension without the risk of 
aspiration. However, colonoscopy carries the risk of perforation.13,14 Currently, no 
randomized controlled trials have been performed comparing duodenal vs. colonic 
delivery of donor feces. Furuya-Kanamori et al. compared upper with lower 
gastrointestinal delivery routes of FMT pooling data of 14 studies.28 They showed that 
FMT via lower gastrointestinal delivery seems to be the most effective route. 
However, the authors did not address the fact that more than half of the patients who 
received donor feces via upper delivery, received less than the recommended 50g of 
donor feces.22,29 Although a recent randomized, open-label, controlled pilot study (N = 
20) showed that nasogastric administration of donor feces appears to be as effective 
as colonoscopic administration30, a randomized controlled trial comparing duodenal 
vs. colonic delivery of donor feces is required to determine the optimal route for FMT 
delivery. Delivery via enema has advantages in its accessibility, since it does not 
require endoscopy or anesthesia. Although administration via enema is well tolerated 
by patients, usually multiple infusions are required to reach clinical cure. In addition, 
some patients have problems with fecal incontinence.25 Nasogastric administration of 
donor feces has been less favored, presumably due to the location of insertion of the 
donor feces.31 
A limitation of our study is its retrospective design. Four out of 43 patients were lost 
to follow-up, and pre-FMT data were incomplete in a subset of patients. Information 
was obtained through telephone calls, and information had to be recalled from 
memory by the patients. Another limitation of this study is that we did not collect 
stool samples before and after FMT. Therefore, data about dynamics of the gut 
microbiota over time are lacking. 
In conclusion, FMT is a very effective treatment for CDI recurrence, with long-term 
benefits over antibiotic use. Importantly, a first post-FMT recurrence of CDI can be 
successfully treated with antibiotics, with a theoretical preference for fidaxomicin. 
FMT remains an invasive procedure and complications do occur. To avoid the risk of 
regurgitation or vomiting after FMT, volume reduction of donor feces suspension 
should be performed without hesitation in case of abdominal symptoms or nausea. In 
patients with risk factors for aspiration, delivery of the donor feces suspension 
through colonoscopy should be considered. In the first month after FMT, antibiotics 




1. Ghose C. Clostridium difficile infection in the twenty-first century. Emerg 
Microbes Infect 2013; 2:e62. 
2. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of 
health care-associated infections. N Engl J Med 2014; 370:1198-208. 
3. Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, 
treatments, and outcomes. Journal of Infection 2009; 58:403-410. 
4. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in 
the United States. N Engl J Med 2015; 372:825-834. 
5. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal 
Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 
2008; 197:435-8. 
6. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 eliminates Clostridium 
difficile and is sparing of bacteroides species during treatment of C. difficile 
infection. Antimicrob Agents Chemother 2009; 53:261-263. 
7. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for 
recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415. 
8. Drekonja D, Reich J, Gezahegn S, et al. Fecal Microbiota Transplantation for 
Clostridium difficile Infection: A Systematic Review. Ann Intern Med 2015; 
162:630-8. 
9. Baxter M, Colville A. Adverse events in faecal microbiota transplant: a review of 
the literature. J Hosp Infect 2015. 
10. Solari PR, Fairchild PG, Noa LJ, Wallace MR. Tempered enthusiasm for fecal 
transplant. Clin Infect Dis 2014; 59:319. 
11. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment 
of Clostridium difficile infection in immunocompromised patients. Am J 
Gastroenterol 2014; 109:1065-71. 
12. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a 
complication of fecal microbiota transplant. Clinical Infectious Diseases 2015; 
61:136-137. 
13. Patel NC, Griesbach CL, DiBaise JK, Orenstein R. Fecal microbiota transplant for 
recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience. 
Mayo Clin Proc 2013; 88:799-805. 
14. Potakamuri L, Turnbough L, Maheshwari A, et al. Effectiveness of fecal 
microbiota transplantation for the treatment of recurrent clostridium difficile 
infection: Community hospital experience. American Journal of 
Gastroenterology 2013; 108:S175. 
15. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota 
transplantation for treatment of Clostridium difficile infection despite 
asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 
108:1367. 
16. Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 
94 patients with recurrent and refractory Clostridium difficile infection using 
single to multiple fecal microbiota transplantation via retention enema. Eur J 
Clin Microbiol Infect Dis 2014; 33:1425-8. 
17. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing 
Clostridium difficile infection in 26 patients: methodology and results. J Clin 
Gastroenterol 2012; 46:145-9. 
18. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term Follow-up Study of Fecal 
Microbiota Transplantation for Severe and/or Complicated Clostridium difficile 
Infection: A Multicenter Experience. J Clin Gastroenterol 2016; 50:398-402. 
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. J 
Chronic Dis 1987; 40:373-383. 
20. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal 
microbiome during and after treatment of Clostridium difficile infection (CDI) 
and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 
2012; 55 Suppl 2:S132-42. 
21. Gweon TG, Kim J, Lim CH, et al. Fecal Microbiota Transplantation Using Upper 
Gastrointestinal Tract for the Treatment of Refractory or Severe Complicated 
Clostridium difficile Infection in Elderly Patients in Poor Medical Condition: The 
First Study in an Asian Country. Gastroenterol Res Pract 2016; 2016:2687605. 
22. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota 
transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile 
infection. Clin Infect Dis 2011; 53:994-1002. 
23. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota 
transplantation for relapsing Clostridium difficile infection. Jama 2014; 
312:1772-8. 
24. Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota 
Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent 
Clostridium difficile Infection: A Randomized Clinical Trial. Jama 2016; 315:142-
9. 
25. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the 
treatment of Clostridium difficile infection: a systematic review. J Clin 
Gastroenterol 2014; 48:693-702. 
26. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series 
involving 18 patients treated with donor stool administered via a nasogastric 
tube. Clin Infect Dis 2003; 36:580-585. 
27. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the 
treatment of Clostridium difficile infection: a review and pooled analysis. 
Infection 2012; 40:643-8. 
28. Furuya-Kanamori L, Doi SA, Paterson DL, et al. Upper Versus Lower 
Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent 
or Refractory Clostridium difficile Infection: A Collaborative Analysis of 
Individual Patient Data From 14 Studies. J Clin Gastroenterol 2016. 
29. Terveer EM, van Beurden YH, van Dorp S, Keller JJ, Kuijper EJ. Is the Lower 
Gastrointestinal Route Really Preferred Over the Upper Gastrointestinal Route 
for Fecal Microbiota Transfer? J Clin Gastroenterol 2016. 
30. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing 
Clostridium difficile infection using a frozen inoculum from unrelated donors: a 
randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58:1515-
22. 
31. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient 
attitudes toward the use of fecal microbiota transplantation in the treatment of 




Appendix A. Questionnaire FU FMT for recurrent Clostridium difficile infection 
General health 
Charlson comorbidity index: 
 Myocardial infarct  
 Heart failure 
 Peripheral vascular disease  
 Cerebrovascular disease  
 Dementia 
 Chronic pulmonary disease 
 Connective tissue disease 
 Ulcer disease  
 Mild liver disease (cirrhosis without portal hypertension of chronic hepatitis) 
 Diabetes (patients receiving oral medication) 
 Hemiplegia 
 Moderate or severe renal disease (serum creatinine level >265 umol/l, 
dialysis, transplantation) 
 Diabetes with end organ damage 
 Any tumour treated in the last 5 years 
 Leukaemia 
 Lymphoma 
 Moderate or severe liver disease (cirrhosis with portal hypertension) 
 Metastatic solid tumour 
 AIDS (CD4 count < 200) 
Do you use any medication at the moment?  
 No 
 Yes, namely (name + dose mediation):………………………………………………………………… 
 
 
Previous Clostridium difficile infection (CDI) 
When did you develop your first episode of CDI (month, year):…………………………………… 
How many episodes of CDI did you experience before FMT:………………………………………… 
How were previous episodes of CDI treated? 
 Oral metronidazole 
 Oral vancomycin 
 Metronidazole and vancomycin 
 Metronidazole and/or tapered regimen of vancomycin 
 Fidaxomicin 
 Other, namely:…………………….………………………………………………………………………………. 
Have you ever been admitted to the hospital because of CDI? 
 No 
 Yes, date (dd-mm-yy).………………………………………………………………………………………….. 
Follow-up after fecal microbiota transplantation (FMT) 
Did you gain weight after FMT? 
 No 
 Yes:………………………kilogram 
Do you have abdominal discomfort on a regular basis since FMT? 
 No 
 Yes 
Have you developed another recurrence of CDI after FMT? 
 No 
 Yes, date (dd-mm-yy)……………………………………………………………………………………………
 Treatment:……..……………………………………………………………………………………………… 
 Treatment successful? 
o Yes 
o No: 
 Date of 2nd recurrence after FMT:……………..…………………… 
 Treatment of 2nd recurrence after FMT:………………………… 
Have you developed another episode of diarrhea or abdominal pain after FMT? 
 No 
 Yes, date:………………………………… Number of days:…………………………………………. 
o Blood in stool 
o Fever 
o Abdominal pain 
o Other complaints, namely:…………………………………………......................... 
o Did you visit a medical doctor at that time: 
 No 
 Yes,  
o Have you been tested for CDI? 
 No 
 Yes, result:…………………………………………………. 
 Did you receive any treatment for the diarrhea? If yes, what 
kind of treatment? 
……………………………………………………………………........................... 
Did you visit the general practitioner or a medical specialist after FMT for any reason? 
 No 
 Yes, date:……………………………………………………………………………………………………………… 
 Reason:………………………………………………………………………………….………….. 
Have you developed an auto-immune disorder after FMT? 
 No 
 Yes, namely:…………………………………………………………………………………………………………. 
 Treatment:………………………………………………………………………………………… 
Have you been admitted to the hospital after FMT? 
 No 
 Yes, date:……………………………..……………………………………………………………………………… 
 Reason:………………………………………………………………………………………..……. 
Did you receive any antibiotic treatment after FMT (for any reason)? 
 No 
 Yes, date:……………………….…………………………………………………………………………………….. 
 Sort of antibiotic treatment:……………………………………………………………… 
Did you start any medication after FMT? 
 No 
 Yes, date:……………… Name medication:……………………………………………………………….. 
 
  
Appendix B. WHO-UMC causality categories 
Causality term Assessment criteria 
 
Certain 
• Event or laboratory test abnormality, with plausible time 
relationship to drug intake 
• Cannot be explained by disease or other drugs 
• Response to withdrawal plausible (pharmacologically, 
pathologically) 
• Event definitive pharmacologically or phenomenologically (i.e. an 
objective and specific medical disorder or a recognised pharmacological 
phenomenon) 




• Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
• Unlikely to be attributed to disease or other drugs 
• Response to withdrawal clinically reasonable 
• Rechallenge not required 
 
Possible 
• Event or laboratory test abnormality, with reasonable time 
relationship to drug intake 
• Could also be explained by disease or other drugs 
• Information on drug withdrawal may be lacking or unclear 
 
Unlikely 
• Event or laboratory test abnormality, with a time to drug intake that 
makes a relationship improbable (but not impossible) 




• Event or laboratory test abnormality 
• More data for proper assessment needed, or 




• Report suggesting an adverse reaction 
• Cannot be judged because information is insufficient or 
contradictory 
• Data cannot be supplemented or verified 
 
